ACADIA PHARMACEUTICALS INC. Investments, Fair Value Disclosure
ACADIA PHARMACEUTICALS INC. (ACAD) had Investments, Fair Value Disclosure of $751.94 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Fair Value Disclosures
us-gaap:InvestmentsFairValueDisclosure · last filed 2026-08-05
- 2026-06-30: Investments, Fair Value Disclosure $751.94M.
- 2026-03-31: Investments, Fair Value Disclosure $672.08M.
- 2025-12-31: Investments, Fair Value Disclosure $666.83M.
- 2025-09-30: Investments, Fair Value Disclosure $744.87M.
| Period end | Investments, Fair Value Disclosure |
|---|---|
| 2026-06-30 | $751.94M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $672.08M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $666.83M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $744.87M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $665.37M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $626.00M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $587.96M 10-K · filed 2026-02-26 |
| 2024-09-30 | $484.17M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $448.02M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $317.65M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $314.79M 10-K · filed 2025-02-27 |
| 2023-09-30 | $291.63M 10-Q · filed 2023-11-03 |
| 2023-06-30 | $364.67M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $411.12M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $395.60M 10-K · filed 2024-02-28 |
| 2022-09-30 | $421.99M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $417.89M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $438.51M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $499.79M 10-K · filed 2023-02-28 |
| 2021-09-30 | $533.91M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $542.34M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $576.95M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $632.58M 10-K · filed 2022-03-01 |
| 2020-09-30 | $632.16M 10-Q · filed 2020-11-04 |
| 2020-06-30 | $631.60M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $630.04M 10-Q · filed 2020-05-08 |
| 2019-12-31 | $623.12M 10-K · filed 2021-02-25 |
| 2019-09-30 | $628.46M 10-Q · filed 2019-10-31 |
| 2019-06-30 | $369.20M 10-Q · filed 2019-08-01 |
| 2019-03-31 | $404.69M 10-Q · filed 2019-05-02 |
| 2018-12-31 | $451.37M 10-K · filed 2020-02-27 |
| 2018-09-30 | $206.58M 10-Q · filed 2018-11-06 |
| 2018-06-30 | $255.78M 10-Q · filed 2018-08-08 |
| 2018-03-31 | $295.97M 10-Q · filed 2018-05-04 |
| 2017-12-31 | $333.54M 10-K · filed 2019-02-27 |
| 2017-09-30 | $365.39M 10-Q · filed 2017-11-07 |
| 2017-06-30 | $414.24M 10-Q · filed 2017-08-08 |
| 2017-03-31 | $465.07M 10-Q · filed 2017-05-09 |
| 2016-12-31 | $523.43M 10-K · filed 2018-02-27 |
| 2016-09-30 | $586.41M 10-Q · filed 2016-11-07 |
| 2016-06-30 | $363.09M 10-Q · filed 2016-08-04 |
| 2016-03-31 | $452.12M 10-Q · filed 2016-05-05 |
| 2015-12-31 | $213.06M 10-K · filed 2017-02-28 |
| 2015-09-30 | $240.22M 10-Q · filed 2015-11-05 |
| 2015-06-30 | $270.54M 10-Q · filed 2015-08-06 |
| 2015-03-31 | $297.48M 10-Q · filed 2015-05-07 |
| 2014-12-31 | $322.06M 10-K · filed 2016-02-29 |
| 2014-09-30 | $337.37M 10-Q · filed 2014-11-10 |
| 2014-06-30 | $354.31M 10-Q · filed 2014-08-05 |
| 2014-03-31 | $369.22M 10-Q · filed 2014-05-06 |
| 2013-12-31 | $185.83M 10-K · filed 2015-02-26 |
| 2013-09-30 | $193.62M 10-Q · filed 2013-11-06 |
| 2013-06-30 | $204.63M 10-Q · filed 2013-08-06 |
| 2013-03-31 | $101.11M 10-Q · filed 2013-05-07 |
| 2012-12-31 | $107.60M 10-K · filed 2014-02-27 |
| 2012-09-30 | $22.75M 10-Q · filed 2012-11-05 |
| 2012-06-30 | $21.12M 10-Q · filed 2012-08-08 |
| 2011-12-31 | $30.73M 10-K · filed 2013-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |